Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney.
The multiple-dose pharmacokinetics of pentamidine were studied in six AIDS patients with acute Pneumocystis carinii pneumonia given infusions of pentamidine isethionate 3.7-4 mg/kg/day i.v. Plasma and urine concentrations of pentamidine of repeated samples taken on days 1, 4 and 7 of treatment were assayed by HPLC. Creatinine clearance Clcr was also determined. On day 7, the area under the plasma concentration versus time curve (AUC) varied fourfold (3263 to 12776 nmol.h/L) between individuals. It was lowest in a patient receiving concomitant treatment with carbamazepine, suggesting that this drug may induce the metabolism of pentamidine. On day 7, a mean of 12% of the dose was excreted unchanged in the urine. Clcr was decreased significantly on day 7 compared with day 1 (mean decrease 31%, range 11-63%). Renal clearance of pentamidine (Clr) decreased over time but always exceeded the Clcr, indicating tubular secretion. The decrease of Clr may be explained by capacity-limited secretion and/or a tubulotoxic effect of the drug. The variation of the AUC values is consistent with interindividual differences in rates of metabolism, which supports individual dosing strategies for pentamidine.
Lidman
C
C
Department of Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Sweden.
Bronner
U
U
Gustafsson
L L
LL
Rombo
L
L
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism*; D008297:Male; D010419:Pentamidine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D016896:Treatment Outcome
D010419:Pentamidine